Novo's CSO Has A Lifetime Product Plan For Diabetes Patients
Executive Summary
Novo Nordisk's executive vice president and chief scientific officer, Dr. Mads Krogsgaard Thomsen, talks to Scrip about the Danish firm's biggest challenges as a leader in the development of diabetes therapies – including the positioning of its numerous marketed type 2 diabetes therapies and how the company can stay innovative in a saturated disease space.
You may also be interested in...
Novo's Tresiba Significantly Reduces Hypoglycemia Versus Lantus In DEVOTE
Novo Nordisk's Tresiba reduced the risk of severe hypoglycemia in type 2 diabetes by 40% compared to Sanofi's standard-of-care insulin Lantus. The data may convince physicians to prescribe longer acting insulins, but their effect on formulary positioning remains to be seen.
2Q Pharma Results Preview: Pfizer, Shire, Merck KGaA, Teva, Novo Nordisk And Allergan
Pfizer, Merck KGaA, Novo Nordisk, Shire, Allergan and Teva are among those pharmaceutical majors still to report their 2Q results. Scrip considers what’s in store.
ADA: Victoza's 'Broad' CV Benefit Leads The Way For Semaglutide
Full cardiovascular (CV) outcomes data for Novo Nordisk AS's leading diabetes therapy, Victoza (liraglutide), show positive effects across a wide range of CV endpoints – placing the company in a strong position with the first GLP-1 product and second ever diabetes therapy to show a benefit on CV mortality.